Abstract
Proteosome inhibitors (PI) are standard therapies for relapsed and/or refractory multiple myeloma (RRMM). Carfilzomib (CAR), an irreversible PI, is associated with greater risk of cardiovascular adverse events (CVAE) compared to bortezomib (BOR), a reversible PI. Whether PIs induce changes in
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
